| Biomarker ID | 1610 |
| PMID | 31045265 |
| Year | 2019 |
| Biomarker | mir-145 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in Gleason Score Upgradation (Without Upgradation: -0.4831 Vs Upgradation: -1.1202) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathway include: MicroRNAs in cancer; Heart Development; miRNAs involved in DNA damage response; SRF and miRs in Smooth Muscle Differentiation and Proliferation |
| Experiment | Gleason Score Upgradation Vs No Upgradation |
| Type of Biomarker | Prognostic |
| Cohort | 45 patients with prostate cancer were included for this study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.03 |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |